Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

Critical minerals on the agenda at IMARC 2025

Australians use more water than we think

Switchgear tech receives sustainable design award

NSW battery regulation moves from policy to action

Partnership to turn cooking oil into fuel

Transforming the treatment experience: Rānui Apartments, New Zealand

Nurse-led regional clinics pilot shows promise

Reusing medical equipment is good for the planet. But is it safe?

Benefits of modern hybrid multicloud platforms in health care

Faster acute kidney injury test in development

FMCG Industry Solutions acquires Ozflow Australia

Shaking up kids' drinks using sustainable packaging

Not all processed fats are bad, study finds

Mondi develops lighter banana box

Food quality testing laboratory being opened in Victoria

Lonza bone marrow and cord blood mononuclear cells

Bioss In Vivo Biosimilar Antibodies

LSBio virology research products

Beckman Coulter Life Sciences IR820 and IR870 infrared dye antibody conjugates

Content from other channels on our network